STOCK TITAN

Evotec SE American Depositary Shares - EVO STOCK NEWS

Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.

Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.

With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.

Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.

Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.

Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.

As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.

Rhea-AI Summary

Bayer and Evotec have updated their strategic collaboration to focus on developing innovative precision treatments for cardiovascular diseases. By leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs), the alliance aims to identify and validate novel targets to build a portfolio of precision cardiology therapeutics. Both companies will contribute drug targets and technology platforms for the development of innovative treatment options. Bayer will handle clinical development and commercialization while sharing responsibilities during pre-clinical development with Evotec. The collaboration seeks to address the high unmet medical need in cardiovascular diseases that are the leading cause of death globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Summary
Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.63%
Tags
-
Rhea-AI Summary
Evotec SE appoints Dr. Christian Wojczewski as the new Chief Executive Officer, effective July 1, 2024. Dr. Wojczewski brings over 20 years of experience in management positions, most recently as CEO of Mediq and at Linde Healthcare. The appointment follows an extensive selection process. The current Interim CEO, Dr. Mario Polywka, will retire at the end of June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
management
Rhea-AI Summary
Evotec SE and Variant Bio, Inc. have entered into a strategic partnership to discover and develop treatments for fibrotic diseases. The collaboration combines Variant Bio's genomic discovery platform with Evotec's R&D expertise to address unmet medical needs in fibrotic indications. The agreement includes research funding, milestones, and royalty payments to Evotec based on program success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
partnership
-
Rhea-AI Summary
Evotec SE will announce its financial results for 2023 on April 24, 2024, and hold a conference call to discuss the results and provide an update on its performance. The conference call will be held in English at 3.00 pm CEST. Webcast and phone details are provided for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
-
Rhea-AI Summary
Evotec appoints Aurélie Dalbiez as Chief People Officer, emphasizing a focus on people strategy, culture, and employee engagement. With over 25 years of HR leadership experience, Aurélie's role highlights Evotec's commitment to investing in its workforce and creating an inclusive work environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
Rhea-AI Summary
Evotec SE and Claris Ventures announce an acceleration framework to streamline programs from Claris's portfolio companies into the clinic. Evotec's integrated platform will provide full range of pre-clinical and clinical development and manufacturing capabilities to Claris's biotech companies. The successful collaboration between Evotec and Claris's portfolio company IAMA Therapeutics has led to an agreement that will benefit other portfolio companies as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has expanded its relationship with Advanced BioScience Laboratories, Inc. to develop a third broadly neutralising antibody (bNAb) against HIV. The collaboration aims to provide large-scale cGMP manufacturing campaigns for the bNAb and a previously developed bNAb for a Phase I clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News
Rhea-AI Summary
Evotec SE is holding a conference call to provide a business update and a statement on its commitment to corporate governance standards. The call will feature the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich, and CEO Dr. Mario Polywka, discussing the company's strategy, recent market developments, and unchanged views on Guidance 2023 and the 2025 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
none
Rhea-AI Summary
Evotec SE (EVT) collaborates with the Crohn's & Colitis Foundation's IBD Therapeutics Incubator to advance drug discovery for inflammatory bowel disease (IBD). The collaboration focuses on developing innovative drug targets addressing fibrosis and impaired intestinal barrier function. Evotec's end-to-end integrated R&D platform will be utilized to translate groundbreaking basic research into medical innovations for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none

FAQ

What is the current stock price of Evotec SE American Depositary Shares (EVO)?

The current stock price of Evotec SE American Depositary Shares (EVO) is $4.47 as of December 20, 2024.

What is the market cap of Evotec SE American Depositary Shares (EVO)?

The market cap of Evotec SE American Depositary Shares (EVO) is approximately 1.5B.

What is Evotec SE?

Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. It provides comprehensive solutions in drug discovery and manufacturing to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations.

What are Evotec's main business segments?

Evotec's business is divided into Shared R&D, which offers drug discovery and manufacturing services, and Just-Evotec Biologics, which provides CDMO services for biologics.

Who are Evotec's partners?

Evotec collaborates with all Top 20 Pharma companies, over 800 biotech companies, academic institutions, and other healthcare stakeholders.

What recent collaborations has Evotec entered into?

Recent collaborations include partnerships with Claris Ventures to accelerate programs into the clinic and with Variant Bio to develop treatments for fibrotic diseases.

How many employees does Evotec have?

Evotec employs over 5,000 people across 18 production sites in Europe and the United States.

What are Evotec's key therapeutic areas?

Evotec focuses on central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

What financial performance did Evotec report in 2023?

Evotec reported a 4% increase in revenues, reaching €781.4 million in 2023, despite challenging economic conditions and a cyber-attack.

What are the future goals of Evotec?

Evotec aims to focus on sustainable and profitable growth, optimizing its operations and continuing to advance its mission of developing effective therapeutics.

What is Just-Evotec Biologics?

Just-Evotec Biologics is a segment of Evotec that offers contract development and manufacturing services for biologics.

What makes Evotec's platform unique?

Evotec’s multimodal platform combines innovative technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec SE American Depositary Shares

Nasdaq:EVO

EVO Rankings

EVO Stock Data

1.55B
354.61M
2.34%
0.13%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hamburg